Positive PR out! So of course this stock is down again on the "Galina can't win for trying" principle but longs WILL BE VINDICATED IMHO, as long as company doesn't do another public offering soon!
Also JIMHO my "gut" tells me that the little birdies whispering merger/ acquisition (with safeguards that the products won't be misappropriated by a big whale that doesn't deliver the goods) might be onto something...
Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences
2 hours 32 minutes ago - DJNF
Galena Biopharma to Present GALE-302 Preliminary Immunological Data Optimizing GALE-301, and the Phase 2 NeuVax(TM) Data Impact on Cancer Survivorship at Two Upcoming Medical Conferences
SAN RAMON, Calif., Oct. 22, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's NeuVax(TM) (nelipepimut-S) and GALE-301 and GALE-302 clinical programs will be presented at two upcoming medical conferences. Details of the presentations are as follows:
Society for Immunotherapy of Cancer (SITC) 30th Anniversary
Conference: Annual Meeting
Poster #: 166
Abstract #: 156 -- the abstract will be available on November
will be published in the Journal for ImmunoTherapy
of Cancer on Wednesday, November 4, 2015.
Title: Preliminary report of a clinical trial supporting
the sequential use of an attenuated E39 peptide (E39')
to optimize the immunologic response to the FBP (E39+GM-CSF)
vaccine
Date: Friday, November 6, 2015
Time: 6:15 p.m. to 7:30 p.m. Eastern time
Location: Prince George's Exhibition Hall at the Gaylord National
Hotel & Convention Center in National Harbor, Maryland
GALE-301 (E39) and GALE-302 (E39' -- variant of E39; previously named J65) are folate binding protein (FB) peptides targeting FBP expressing tumors. The data to be presented at SITC is from a single-center, randomized, single-blinded, three-arm Phase 1b study of GALE-301 and GALE-302 in patients with breast or ovarian cancer diagnosis who have been treated by standard of care and are without evidence of disease. The primary endpoint of the trial is immunological and designed to determine which of the three primary vaccination sequence strategies maximizes long-term specific immunity defined as E39-specific cytotoxic T lymphocytes (CTLs) six months following completion of the primary vaccination series.
33rd Annual Chemotherapy Foundation Symposium: Innovative
Conference: Cancer Therapy for Tomorrow(R)
Poster #: 309
Title: NeuVax(TM) (nelipepimut-S) for the prevention of recurrence
in HER2-expressing node positive breast cancer patients
Date: Wednesday, November 4, 2015
Time: 6:00 p.m. to 7:00 p.m. Eastern time
Location: Crown Plaza Hotel, New York, NY
In 2014, it is estimated there are 14.5 million cancer survivors in the United States. By 2024, it is projected there will be 19 million cancer survivors (DeSantis CE et al., 2014). In breast cancer patients, 50--60% who are HER2 IHC
